The advent of novel strategies has shifted the treatment paradigm of metastatic hormone-sensitive prostate cancer (mHSPC) from androgen deprivation therapy (ADT) monotherapy to combination therapies.1 Upfront addition of chemotherapy or androgen receptor (AR) inhibitors to ADT has demonstrated an improved overall survival (OS) and become a new standard of care (SoC) in this therapeutic area.2 The early treatment intensification is particularly important and beneficial to mHSPC patients with high volume of disease.3,4 In an interview with Omnihealth Practice, Dr. Lee, Siu-Hong discussed the unmet needs in mHSPC, emphasizing the importance of using combination therapy for the high-volume patients. He also stressed the significance of monitoring prostate-specific antigen (PSA) response and shared a clinical case of a 70-year-old male diagnosed with de novo mHSPC with high volume of disease who was managed with upfront ADT + enzalutamide, then achieving a rapid reduction in the serum PSA levels.
